Suppliers and packagers for generic pharmaceutical drug: octreotide acetate

octreotide acetate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232	NDA	Chiesi USA, Inc.	10122-550-28	4 BLISTER PACK in 1 DOSE PACK (10122-550-28) / 7 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK	2020-07-06
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232	NDA	Amryt Pharmaceuticals Designated Activity Company	69880-120-28	4 BLISTER PACK in 1 DOSE PACK (69880-120-28) / 7 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK	2020-07-06
Fresenius Kabi Usa	OCTREOTIDE ACETATE	octreotide acetate	INJECTABLE;INJECTION	077450	ANDA	Fresenius Kabi USA, LLC	63323-378-05	1 VIAL, MULTI-DOSE in 1 CARTON (63323-378-05) / 5 mL in 1 VIAL, MULTI-DOSE	2006-03-14
Fresenius Kabi Usa	OCTREOTIDE ACETATE	octreotide acetate	INJECTABLE;INJECTION	077450	ANDA	Fresenius Kabi USA, LLC	63323-379-05	1 VIAL, MULTI-DOSE in 1 CARTON (63323-379-05) / 5 mL in 1 VIAL, MULTI-DOSE	2006-03-14

Last updated: May 24, 2026

treotide Acetate Suppliers, API Manufacturers, and Contract Manufacturing Landscape (2026)
Octreotide acetate is supplied globally as an API and as finished-dose products for oncology and endocrinology indications. The market spans originator supply, branded generics, and contract manufacturing of long-acting injectables (LAR) and short-acting injections. The supplier set is dominated by: (1) API producers supplying octreotide acetate to multiple formulation manufacturers, and (2) specialized sterile injectables CDMOs with capability for depot microspheres or ready-to-inject pens/vials.

Which companies supply octreotide acetate API and who manufactures the finished drug?

Answer: Octreotide acetate supply is split across API manufacturers and finished-dose manufacturers. API and formulation supply chains often cross-license or repackage through brand/generic programs. Long-acting octreotide formulations (LAR) concentrate manufacturing know-how in sterile depot systems, while short-acting octreotide acetate supports simpler sterile aqueous injectable processes.

API suppliers: what role do they play in octreotide acetate supply?

API producers provide octreotide acetate as the peptide active ingredient, typically for:

• Short-acting solutions (aqueous injection)
• Long-acting LAR microsphere formulations (depot suspension)

Long-acting products generally require specialized sterile manufacturing and particle/microsphere characterization control, which pushes finished-dose manufacturing toward dedicated sterile and depot-capable suppliers.

Finished-dose manufacturers: who commercializes octreotide acetate products?

Finished-dose supply usually includes:

• Branded originator long-acting and short-acting products (marketed under brand names in different geographies)
• Branded generics and multisource offerings
• Contract manufacturing for label holders and distributors

What suppliers make the long-acting octreotide (octreotide acetate LAR) and why does it narrow the supplier pool?

Answer: Long-acting octreotide acetate LAR requires sterile, depot-microsphere manufacturing under tight particle, viscosity, and suspension stability specifications. That narrows the supplier pool versus short-acting injection.

Manufacturing complexity for octreotide acetate LAR

Key constraints shaping supplier selection:

• Microsphere formation and controlled drug loading
• Depot suspension quality (particle size distribution, homogeneity, re-suspendability)
• Sterile fill-finish for kit configurations (often including prefilled components or kit assembly)
• Stability across temperature excursions during distribution and storage

Typical product formats influenced by suppliers’ capabilities

• Pre-measured kits for intramuscular injection
• Depot suspension vials or prefilled systems depending on market authorization

Which suppliers cover short-acting octreotide acetate injection (solution) supply?

Answer: Short-acting octreotide acetate injection has a larger universe of suppliers due to comparatively simpler sterile aqueous processes versus LAR depot microspheres, but it still requires strong sterile manufacturing and peptide handling controls.

What drives qualification of solution injectables suppliers?

• Peptide stability in aqueous formulation and pH constraints
• Control of aggregation and degradation products
• Sterile filterability and fill-finish process control
• Container closure compatibility (vial, syringe, or pen depending on market)

How do supplier regions and authorizations affect octreotide acetate availability?

Answer: Supply availability is shaped by which finished-dose manufacturers hold local approvals and which API lots are qualified in each dossier. Regional approvals can delay entry when a manufacturer substitutes a new API source or changes manufacturing sites.

Regulatory drivers for supplier substitutions

• US FDA and EU GMP expectations for peptide drug substance and drug product
• Site-specific manufacturing in EU/US dossiers
• Patient safety and batch consistency in sterile injectables

What is the Orange Book status of octreotide acetate products and how does that impact sourcing?

Answer: Multiple octreotide acetate products have distinct exclusivity and patent landscapes, which affects when generics or authorized LCMs can supply. In practice, sourcing is influenced by the identity of the authorized finished-dose manufacturers, not just API availability.

How Orange Book listings shape supplier contracting

• Patent-protected strengths or dosage forms limit multisource competition
• Label holders may lock preferred suppliers to avoid formulation changes
• Settlement-driven licensing can determine which generic manufacturers can ship

What generic entry risks exist for octreotide acetate formulations based on supplier and manufacturing constraints?

Answer: Entry risk is highest for LAR depot products due to higher CMC burden (microspheres and depot characteristics). Solution products face fewer CMC barriers but still require proven comparability and sterile manufacturing robustness.

Where delays typically occur

• Depot particle specification bridging and stability program outcomes
• Sterile fill-finish process validation and batch release performance
• Kit assembly or components sourcing timelines

Which contract manufacturing organizations (CDMOs) are positioned for octreotide acetate peptide sterile injectables?

Answer: Octreotide acetate manufacturing is typically handled by CDMOs that can support:

• Sterile sterile fill-finish with peptide-specific handling
• Depot microsphere manufacturing for LAR
• Scale-up and clinical-to-commercial transfer

CDMO selection criteria for octreotide acetate

• Demonstrated capability for peptide injectables and depot systems
• EU GMP and US FDA inspection readiness
• Ability to manage container closure, kit assembly, and global serialization needs
• QA release and stability track record with injectable peptides

How do suppliers typically structure supply contracts for octreotide acetate?

Answer: Supply contracting generally splits into:

• API supply agreements (API producer to formulation manufacturer)
• Finished-dose manufacturing agreements (CDMO to brand/generic label holder)
• Global distribution agreements (label holder to wholesalers and tenders)

Risk allocation patterns

• API quality and CoA responsibilities
• Change control on manufacturing sites and analytical methods
• Forecasting and batch scheduling for sterile injectables

What are the commercial implications of supplier concentration for octreotide acetate?

Answer: Supplier concentration is more acute in LAR due to depot manufacturing specialization. Supply disruptions can create shortfalls even if API is available, because finished-dose manufacturing is the bottleneck for sterile depot products.

Exposure areas for procurement and business continuity

• Single-site manufacturing dependency for LAR
• Long lead times for sterile fill-finish and kit components
• Regulatory constraints on rapid substitution

How does octreotide acetate supplier strategy compare with competing somatostatin analogs?

Answer: Compared with other somatostatin analogs (for example lanreotide depot), octreotide acetate LAR has similar depot manufacturing constraints: fewer eligible suppliers, higher CMC burden, and tighter qualification cycles. Procurement strategy usually prioritizes CDMOs with depot and peptide sterile capability.

Supplier overlap implications

• Some CDMOs support multiple depot injectables, enabling cross-program learning and capacity buffering
• Brand/generic label holders may use the same CDMO network across products, improving supply resilience

---

Key Takeaways

• Octreotide acetate supply is divided between API producers and finished-dose manufacturers, with depot-capable CDMOs dominating octreotide acetate LAR supply.
• LAR manufacturing constraints narrow the supplier pool and make finished-dose availability the binding constraint more often than API availability.
• Short-acting solutions generally have more supplier options due to simpler sterile aqueous processes, but they still require peptide stability and sterile fill-finish capability.
• Competitive dynamics are driven by product-specific regulatory status and patent/exclusivity timelines, which affect which label holders can ship and which finished-dose manufacturers can supply.
• Supplier concentration creates supply-chain exposure risks, especially for LAR kits and depot suspensions.

FAQs

1. What is the difference between octreotide acetate API supply and octreotide acetate LAR finished-dose manufacturing?
2. Which manufacturing capabilities are most critical for sterile depot microsphere injectables like octreotide acetate LAR?
3. How do API source changes affect regulatory approvals for octreotide acetate drug products?
4. What drives lead times for octreotide acetate LAR kit assembly and sterile fill-finish?
5. How should procurement evaluate supplier qualification for octreotide acetate peptides versus small molecules?

References

1. U.S. FDA, “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” (Accessed 2026).
2. European Medicines Agency (EMA), “EU GMP Guidelines and related guidance for sterile manufacturing.” (Accessed 2026).